Disease areas
Cardiology
Mapping prevention, diagnostics and access pathways for cardiovascular care.
Cardiometabolic
Tracking risk, prevention and access in metabolic and vascular health.
Eye Disease
Following diagnostics, treatment access and equity in vision care.
Infectious disease
Tracking diagnostics, resistance, prevention and access across infection pathways.
Neurology
Mapping early diagnosis, biomarkers and access in brain health.
Oncology
Following testing, treatment access and equity across cancer pathways.
Cardiology
See all →
Europe: the EU Cardiovascular Health Plan is becoming the “cancer plan” moment for heart disease
A new Lp(a) threshold could reshape cardiovascular risk assessment
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
Africa’s Cardiovascular Decade Is a System-Design Problem
Inherited Lipid Screening Becomes Europe’s Prevention Test
ATTR Gene Editing Restarts, But Safety Becomes the Access Question
Routine CT Scans Could Become a Heart Failure Early-Warning System
Risk Prediction Cannot Simply Be Imported From Europe
Personalised Cardiology Needs a Digital Fabric, Not Just More Data
Cardiometabolic
See all →
The next cardiometabolic battleground is ultra-processed food
ADA 2026 findings show diabetes drugs are no longer just chasing glucose
Physical activity continues to strengthen its case as a cross-disease prevention strategy
Can cortisol become the next target in type 2 diabetes?
Ozempic and Eye Health: Balancing Metabolic Benefits with Vision Risks
Europe’s Safe Hearts Plan Makes Prevention a Political Test
AI Diabetes Tools Need Infrastructure Before Scale
Diabetes Tech Moves From Optional Add-On to Earlier Care
Obesity Care Starts Moving Beyond BMI
Canada’s Generic Semaglutide Approval Tests GLP-1 Affordability
Eye Disease
See all →
The Air We Breathe May Be Shaping the Future Burden of Blindness
Ozempic and Eye Health: Balancing Metabolic Benefits with Vision Risks
Diabetic Eye Screening Is Becoming Risk-Based
Abu Dhabi Puts Rare Eye Gene Therapy on the Regional Map
AI Eye Screening Has an Image Quality Problem
AI Retinal Screening Moves Into the Diabetes Clinic
Geographic Atrophy Forces Europe to Define Meaningful Vision Benefit
Eye Health Moves From Charity Case to Investment Case
Infectious disease
See all →
Lenacapavir Turns HIV Prevention Into an Access Stress Test
WHO’s New AMR Plan Makes Stewardship and Access a Single Test
Hepatitis B Functional Cure Moves Closer, But Access Still Starts With Diagnosis
Ebola PHEIC Turns Outbreak Control Into a Preparedness Test
The AMR Pipeline Is Too Thin for the Threat Ahead
TB Diagnosis Moves Closer to the Patient
Hepatitis Elimination Is Still Losing Patients Before Diagnosis
Lenacapavir Turns HIV Prevention Into an Access Stress Test
WHO’s AMR Plan Turns Access Into Preparedness
Neurology
See all →
Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority
Alzheimer’s Blood Testing Moves the Disease Clock Earlier
Huntington’s Disease Gets an Oral Target-Engagement Signal
A Urine Test for Alzheimer’s Would Change the Access Conversation
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
AI in Cardiology Moves From Promise to Policy Pressure
Cyberbullying Becomes a Youth Mental Health Policy Target
Alzheimer’s Agitation Gets a New Drug, But Care Pathways Still Lag
Rare Epilepsy Moves Toward Treating the Cause
Oncology
See all →
Cancer Sequencing Becomes the Operating System of Precision Oncology
Personalised Cancer Vaccines Show Longer-Term Staying Power
Oral SERDs Face the Hard Test: Where Do They Actually Fit?
Prostate Cancer Value Starts Counting Cognition
China’s PD-1/VEGF Bet Challenges the Lung Cancer Backbone
The ASCO Drug Race Still Runs Through Genomic Testing
High-Risk Prostate Cancer Moves Before the Metastatic Clock Starts
Physical activity continues to strengthen its case as a cross-disease prevention strategy
An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer
